Clinical research shows that people with higher BMIs are more likely to see significant benefits from prescription weight loss medications like Ozempic
While it can indirectly influence hormonal balance through weight loss, there is no direct evidence suggesting it directly affects the menstrual cycle
Currently, not much is known about the physiology of Neurotensin, INSL-5 and Xenin
Specifically, a study of zibotentan, a highly selective endothelin A ERA, in combination with dapagliflozin in participants with type 2 diabetes (NCT05570305) is currently underway, with similar phase 2 trials in type 1 diabetes being proposed
The role of NADPH, the reduced form of nicotinamide adenine dinucleotide phosphate (NADP + ), in mediating inflammatory and anti-inflammatory responses in activated myeloid cells has been well-established in the past decades

AOD-9604: Direct Lipolysis Theory AOD-9604 is a modified C-terminal fragment of human growth hormone, designed to isolate GH's fat-metabolizing properties: Lipolysis Activation: Theorized to stimulate fat breakdown through beta-3 adrenergic receptor pathways No IGF-1 Stimulation: Unlike full GH, AOD-9604 does not elevate insulin-like growth factor 1 Non-diabetogenic: Does not impair glucose metabolism or insulin sensitivity No Anabolic Effects: Does not promote muscle or organ growth Semaglutide: Central Regulation Theory Semaglutide achieves weight loss through systemic metabolic regulation: Hypothalamic Appetite Control: GLP-1 receptors in the brain reduce hunger and food-seeking behavior Gastric Emptying: Slowed stomach emptying promotes early satiety Insulin Optimization: Glucose-dependent insulin secretion improves metabolic efficiency Reward Pathway Modulation: Reduced hedonic eating and food reward responses The fundamental difference: AOD-9604 attempts to "burn" existing fat directly, while Semaglutide reduces caloric intake through appetite and satiety mechanisms, creating an energy deficit that leads to fat loss
